secwatch / observer
8-K filed June 1, 2023, 7:59 PM ET ticker DSGN CIK 0001807120
other confidence high sentiment neutral materiality 0.10

Design Therapeutics shareholders re-elect three directors, ratify EY as auditor

Design Therapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Design Therapeutics, Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2023-05-31 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-05-31
Exact text from the filing
The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 52,499,051 437 123,262 0
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Design Therapeutics, Inc. shareholders approved Election of three Class II Directors at the 2023-05-31 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-05-31
Exact text from the filing
The Company’s stockholders elected the three persons listed below as Class II Directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Simeon George, M.D. 47,533,466 1,741,637 3,347,647 Arsani William, M.D. 48,972,541 302,562 3,347,647 Deepa Prasad 48,988,793 286,310 3,347,647
View on SEC.gov

Browse all shareholder votes →

Design Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-23-159009
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.